'It is not going away': Virologist fund manager Dr Ogden discusses all things coronavirus

Single vaccine 'not enough' to treat patients

Lauren Mason
clock • 7 min read

The coronavirus pandemic has changed how the world's healthcare systems and biotechnology companies will operate irrevocably as Covid-19 "isn’t going to go away", according to virologist and manager of the AUS$335m Platinum International Healthcare fund Dr Bianca Ogden.

Ogden, who obtained a PhD in virology, and previously worked as a scientist for Johnson & Johnson and Novartis before launching the portfolio in 2003, said comparisons can be made between the Covid-19 strain of the coronavirus and HIV, in that it cannot be eradicated via a single vaccine. "When you look at the family of coronaviruses, they don't tend to go away. They were compared relatively early on to the HIV virus; it is a different family, but similarly it is something we will have to live with, and it means we will have to adjust how we live," she explained. "Coronaviruses have b...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment

Party politics: Why investors should celebrate AIM's 30th birthday, even if the government won't

Party politics: Why investors should celebrate AIM's 30th birthday, even if the government won't

AIM has helped 4,000 businesses raise £135bn since launch

Eustace Santa Barbara
clock 19 June 2025 • 4 min read
AIM at 30: Why advisers should take a fresh look at the UK's junior market

AIM at 30: Why advisers should take a fresh look at the UK's junior market

'We see AIM as a jewel in the crown with long-term appeal for the right clients'

Oliver Brown
clock 17 June 2025 • 4 min read
Taking the rough with the smooth: How to navigate global market volatility

Taking the rough with the smooth: How to navigate global market volatility

'Like investing, smoothing isn't one-size-fits-all'

James Tothill
clock 13 June 2025 • 4 min read